CM has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, Innosuisse, the University Hospital Basel, the University of Basel; Abbott, Astra Zeneca, Beckman Coulter, Boehringer Ingelheim, BRAHMS Thermo Fisher Scientific, Idorsia, LSI Medience Corporation, Novartis, Ortho Diagnostics, Quidel, Roche, Siemens, Singulex, SpinChip, Sphingotec, and Upstream, all paid to the institution. He has also received speaker honoraria/consulting honoraria from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Idorsia, Novartis, Novo Nordisk, Osler, Roche, SpinChip, and Sanofi, again all paid to the institution. CRM is supported by the Swiss National Science Foundation and by Innosuisse and has currently ongoing research collaborations with Eli-Lilly, Novartis, and IBSA, all unrelated to this topic. FG has been supported by Deutsche Herzstiftung and has received speaker honoraria from AstraZeneca. FM has been supported by Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939) and Deutsche Herzstiftung. Saarland University has received scientific support from Ablative Solutions, Medtronic, and ReCor Medical. Until May 2024, FM has received speaker honoraria/consulting fees from Ablative Solutions, AstraZeneca, Inari, Medtronic, Merck, Novartis, Philips, and ReCor Medical. JB has been supported by an Edinburgh Doctoral College Scholarship and research grants from the University of Basel, the University Hospital of Basel, the Division of Internal Medicine, the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner Foundation, the Swiss National Science Foundation, and the Swiss Heart Foundation, and has received honoraria from Siemens, Roche Diagnostics, Ortho Clinical Diagnostics, Quidel Corporation, and Beckman Coulter, and travel support from Medtronic and Vascularmedical, all outside the submitted work. MKunz has received consulting fees from Merck (Merck KGaA). MS has received speaker honoraria or consulting fees from Apontis, AstraZeneca, BMS, CSL Vifor, Daiichi Sankyo, Novartis, Pfizer, and TAD, all outside the work submitted. UL has received speaker honoraria or consulting fees from Amgen, Boehringer, Daiichi Sankyo, Novartis, Sanofi outside the work submitted.

The other authors have nothing to declare.